133430-99-6

Usage

Uses

Used in Organic Synthesis:
4-(tert-butyldimethylsilyloxy)iodobenzene is used as a reagent for the introduction of the tert-butyldimethylsilyl (TBS) protecting group in organic synthesis. Its selective protection of hydroxyl groups in complex molecules and easy removal under mild conditions make it a valuable tool in synthetic chemistry.
Used in Pharmaceutical Industry:
4-(tert-butyldimethylsilyloxy)iodobenzene is used as a precursor for the synthesis of various biologically active compounds and pharmaceutical intermediates. Its ability to selectively protect hydroxyl groups and its sensitivity to moisture and air contribute to the development of novel drug candidates with improved efficacy and safety profiles.

Upstream product

• 288-32-4 1H-imidazole 
• 540-38-5 p-Iodophenol 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Downstream Products

• 133910-15-3 22-phenyl>-de-A,B-24-norcholan-8β-ol 
• 136053-34-4 1-[(tert-butyldimethylsilyl)oxy]-4-ethynylbenzene 
• 886054-78-0 (4-(2,2'-bithiophen-5-yl)phenoxy)(tert-butyl)dimethylsilane 
• 864157-05-1 1-{4-[4-(tert-butyl-dimethyl-silanyloxy)-phenyl]-but-3-ynyl}-1H-[1,2,3]triazole 
• 864157-02-8 4-(4-[1,2,3]triazol-1-yl-but-1-enyl)-phenol 
• 1025446-83-6 C₅₃H₈₀O₅Si₂ 
• 1019209-34-7 1,3,5-tris[4-(tert-butyldimethylsilyloxy)phenylethynyl]benzene 
• 1034619-76-5 (2-(4-(tert-butyldimethylsilyloxy)phenyl)-4-chloro-6-(methylthio)pyrimidin-5-yl)-(phenyl)methanone 
• 1206482-51-0 ((3R,5R,7R)-3-(benzyloxy)-1-(4-(tert-butyldimethylsilyloxy)phenyl)-5-(4-methoxybenzyloxy)octadeca-1,9-diyn-7-yloxy)(tert-butyl)dimethylsilane 
• 1206482-43-0 ((3R,5S,7R)-3-(benzyloxy)-1-(4-(tert-butyldimethylsilyloxy)phenyl)-5-(4-methoxybenzyloxy)icosa-1,9-diyn-7-yloxy)(tert-butyl)dimethylsilane 
• 1206482-44-1 ((3R,5S,7R)-3-(benzyloxy)-1-(4-(tert-butyldimethylsilyloxy)phenyl)-5-(4-methoxybenzyloxy)octadeca-1,9-diyn-7-yloxy)(tert-butyl)dimethylsilane 
• 1312542-55-4 4-{4-[(tert-butyldimethylsilyl)oxy]phenyl}benzo[c][1,2,5]thiadiazole 
• 1402154-11-3 (2R,8S,9S,10R,13S,14S,17S)-methyl 17-(4-hydroxybenzoyl)-2,10,13-trimethyl-2,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3-carboxylate 
• 1426660-40-3 2-(4-(tert-butyldimethylsilyloxy)phenyl)-4H-chromen-4-one 

Relevant academic research and scientific papers

Synthesis and biological evaluation of p-carborane bisphenols and their derivatives: Structure-activity relationship for estrogenic activity

p-Carborane bisphenols and their derivatives were prepared and evaluated for binding affinity to estrogen receptor α. Their estrogenic activity was evaluated by means of transcriptional assay and cell proliferation assay using MCF-7 cell lines. 1,12-Bis(4

Design and synthesis of an activity-based protein profiling probe derived from cinnamic hydroxamic acid

In our continued effort to discover new anti-hepatitis C virus (HCV) agents, we validated the anti-replicon activity of compound 1, a potent and selective anti-HCV hydroxamic acid recently reported by us. Generally favorable physicochemical and in vitro absorption, distribution, metabolism, and excretion (ADME) properties exhibited by 1 made it an ideal parent compound from which activity-based protein profiling (ABPP) probe 3 was designed and synthesized. Evaluation of probe 3 revealed that it possessed necessary anti-HCV activity and selectivity. Therefore, we have successfully obtained compound 3 as a suitable ABPP probe to identify potential molecular targets of compound 1. Probe 3 and its improved analogs are expected to join a growing list of ABPP probes that have made important contributions to not only the studies of biochemical and cellular functions but also discovery of selective inhibitors of protein targets.

CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES

The present disclosure provides a class of compounds including a ligand moiety that specifically binds to a cell surface receptor, such as a mannose-6-phosphate receptor (M6PR) or a cell surface asialoglycoprotein receptor (ASGPR). The cell surface M6PR or ASGPR binding compounds can trigger the receptor to internalize into the cell a bound compound. The ligand moieties of this disclosure can be linked to a variety of moieties of interest without impacting the specific binding to, and function of, the cell surface receptor, e.g., M6PR or ASGPR. Also provided are compounds that are conjugates of the ligand moieties linked to a biomolecule, such as an antibody, which conjugates can harness cellular pathways to remove specific proteins of interest from the cell surface or from the extracellular milieu. Also provided are methods of using the conjugates to target a polypeptide of interest for sequestration and/or lysosomal degradation.

Total Synthesis of Asparenydiol by Two Sonogashira Cross-Coupling Reactions Promoted by Supported Pd and Cu Catalysts

Asparenydiol, which is an important natural compound with potential pharmacological activities, was synthesized through two Sonogashira cross-coupling reactions catalyzed by supported Pd and Cu catalysts and by a Mitsunobu etherification. The optimization

ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE

The present invention relates to compounds of formula (I)-(VI) and/or (A)-(H-I), or any subgenera thereof, or a pharmaceutically acceptable salt, tautomer or stereoisomer. The compounds of the present disclosure are useful in modulating androgen receptor activity and for treating cancer including prostate cancer.

NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME

Compound of formula (I): wherein A1, A2, Ra, Rb, Rc, Rd, R3, R4, X, Y and G are as defined in the description, and their use in the manufacture of medicaments.

Efficient synthesis of 3-benzoyl Benzo[b]thiophenes and raloxifene via Mercury(II)-Catalyzed cyclization of 2-alkynylphenyl alkyl sulfoxides

The unique selective estrogen receptor modulator, Raloxifene (1), and antitubulin agent 2 were synthesized through the key intermediate, 4-methoxybenzyl 2-bromo-4-methoxyphenyl sulfoxide (6), respectively. It was found that compared with the o-sulfanyl aryl bromides, the sulfinyl group at ortho position accelerated the Sonogashira coupling reaction of aryl bromides. Thus, compound 6 was coupled with 3,4,5-trimethoxyphenyl acetylene, followed by mercury-catalyzed cyclization reaction afford compound 2 in 79% overall yield. Raloxifene (1) was prepared from compound 6 in four steps and 33% overall yield via coupling reaction with 1-trimethylsily-2-(4-tert-butyldimethylsiloxy)phenylethyne, mercury-catalyzed cyclization reaction, alkylation and demethylation.

AN ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USED THEREOF

The present invention relates to isoxazole derivatives, including pharmaceutical compositions and for the preparation of isoxazole derivatives. And more particularly the present invention provided a pharmaceutical composition of isoxazole derivatives for activation of Farnesoid X receptor(FXR, NR1H4).

Sulfoxide compound and method of producing benzothiophene derivatives using the same

A sulfoxide compound and method of producing benzothiophene derivatives using the same are provided. The sulfoxide compound is represented by formula (I), wherein R1 and R2 are individually and independently benzoyl group; alkyl, acyl or silyl group of C1-C6 straight chain or branched chain; or alkenyl group of C3-C6 straight chain or branched chain; and X is halogen atom. The sulfoxide compound reacts with alkynyl compound, and then the synthesis efficiency of benzothiophene derivatives can be effectively increased.

Synthesis and evaluation of (E)-2-(5-phenylpent-2-en-4-ynamido)cyclohex-1-ene-1-carboxylate derivatives as HCA2 receptor agonists

Novel series of compounds consisting of 2-amidocyclohex-1-ene carboxylate and phenyl parts which are connected by enyne (compounds 2a–f), but-1-yne (compounds 4a–j), and phenylethylene (compounds 5a–f) linkers as HCA2 full agonists were designed and their